^
Association details:
| Biomarker: | FGFR2-AHCYL1 fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Truseltiq (infigratinib) (FGFR inhibitor) + PD173074 (Tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma
Excerpt:
...cholangiocarcinoma patients without KRAS/BRAF/ROS1 alterations and identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1...Treatment with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074 effectively suppressed transformation.
DOI:
https://doi.org/10.1002/hep.26890
